Eli Lilly | LLY - Interest Income


Eli Lilly reported $65M in Interest Income for its fiscal quarter ending in September of 2025.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Abbott USD 78M 1000K Dec/2025
ALKERMES USD 8.54M 3.59M Mar/2026
AstraZeneca USD 73M 62M Mar/2026
Baxter International USD 11M 1000K Dec/2025
Biogen USD 37.9M 700K Mar/2026
Drreddys Laboratories INR 796M 332M Dec/2025
Eli Lilly USD 65M 25M Sep/2025
Gilead Sciences USD 95M 7M Dec/2025
GlaxoSmithKline GBP 22M 96M Mar/2026
Glaxosmithkline GBP 26M 24M Sep/2025
J&J USD 2.14 237M Mar/2026
Medtronic USD 114M 23M Jan/2025
Merck USD 69M 27M Dec/2025
Pfizer USD 115M 51M Mar/2026
Phibro Animal Health USD 0.08 0.09 Dec/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 33M 81M Dec/2025
Sanofi EUR 114M 38M Sep/2025
United Therapeutics USD 43.2M 3.2M Dec/2025
Zoetis USD 25M 1000K Dec/2025